Sanquin Health Solutions

Sanquin Health Solutions

Ziekenhuizen en gezondheidszorg

Amsterdam, North Holland 2.794 volgers

Unlocking the potential of blood and science

Over ons

The Sanquin Health Solutions Group (SHS) ecosystem and their innovation partners stimulate and facilitate developments and innovations in the field of Transfusion Medicine, Heamatology, Immunology and Oncology. By doing this, we provide future's medicines, vaccines, diagnostic tests and treatment methods.

Branche
Ziekenhuizen en gezondheidszorg
Bedrijfsgrootte
201 - 500 medewerkers
Hoofdkantoor
Amsterdam, North Holland
Opgericht
2021
Specialismen
Diagnostic services, Reagents, Immunomonitoring services, Innovation, Transfusion medicine, Immunology, Oncology, Heamatology, Hematology, Medtech, Biotech, Consulting, Education, Biologics, contract research, Antibodies, Bioanalysis, Ligand Binding Assays, Mass Spectrometry, Pharmaceuticals en Healthcare

Updates

  • 𝗝𝘂𝘀𝘁 𝟮𝟮 𝗱𝗮𝘆𝘀 𝗹𝗲𝗳𝘁! 𝗝𝗼𝗶𝗻 𝘂𝘀 𝗶𝗻 #𝗔𝗺𝘀𝘁𝗲𝗿𝗱𝗮𝗺 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗧𝗗𝗠 𝗼𝗳 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗼𝗻 𝗗𝗲𝗰𝗲𝗺𝗯𝗲𝗿 𝟲𝘁𝗵! Sanquin 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀 together with Reade - revalidatie & reumatologie and Amsterdam UMC, is hosting a one-day symposium to explore cutting-edge insights into personalized biologic dosing. This event is geared towards pharmacologists, pharmacists, policy makers, drug developers, and clinicians who want to stay ahead in the evolving field of therapeutic drug monitoring of biologics.   𝗪𝗵𝗮𝘁 𝘁𝗼 𝗲𝘅𝗽𝗲𝗰𝘁: The symposium features a range of key topics: - Finding the Therapeutic Window - Dosing Down Strategies - Model-Informed Precision Dosing - Beyond TDM of Antibody Biologics   If personalized medicine, precision dosing, and impactful case studies sound intriguing, this symposium is for you. Explore the full program and register here: [https://lnkd.in/efd3Kraw].   Accreditation by: Nederlandse Vereniging van Ziekenhuisapothekers (NVZA), Nederlandse Vereniging voor Reumatologie (Dutch Society for Rheumatology), Nederlandse Vereniging van Maag-Darm-Leverartsen (NVMDL) and Nederlandse Internisten Vereniging   Event endorsed by: International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) With the support of: Takeda, Eli Lilly and Company, and BIOSYNEX Diagnostics   Organizing committee: Floris Loeff, Mark Löwenberg, Gertjan Wolbink, Geert DHaens, Ron Mathôt, Phyllis Spuls, Theo Rispens, and Annick de Vries are excited to welcome you to an engaging day of insights and networking.   Secure your spot—register today!

    • Geen alternatieve tekst opgegeven voor deze afbeelding
  • We are proud to announce that our Monocyte Activation Test (MAT) expert Marijke Molenaar- de Backer is invited to speak at a meeting funded by Bill & Melinda Gates Foundation. Marijke will discuss how to implement MAT for biologics at The Animal-Free Safety Assessment (AFSA) Collaboration workshop. https://lnkd.in/gsdJgEau Marijke will provide insights into the use of different MAT formats in testing human albumin preparations. She will also demonstrate how the MAT can be used for testing outer membrane vesicle (OMV) vaccines. This adaptation had some challenges, as OMV vaccines typically already activate the monocytes by themselves. #MAT #MonocyteActivationTest #vaccines Sanquin Annick de Vries

    • Geen alternatieve tekst opgegeven voor deze afbeelding
  • How to assess immunogenicity? The latest insights advise a fit-for-purpose approach where immunogenicity assessment is considered as a biomarker. Above all: immunogenicity testing should provide informative data, dependent on the context of use. This was the result of the European Bioanalysis Forum (EBF) Focus Workshop, including our principal scientist Karien Bloem, that critically re-evaluated the current paradigm for clinical immunogenicity assessment. Based on 20+ years of accumulating knowledge and experience these findings are published here: https://lnkd.in/eev7Yuug Annick de Vries Floris Loeff #EBF #Bioanalysis #Immunogenicity #SanquinHealthSolutions

    • Quote ”Happy to see that the measurements for immunogenicity of biologics are moving towards relevant measurements for patients. This can close the gap between hospital testing and regulated bioanalysis.” 
From Karien Bloem, PhD, Principal scientist, R&D, Sanquin Diagnostic Services
  • This year, we are proud to host the 17th European Symposium on Platelet and Granulocyte Immunobiology (ESPGi), a premier event for exploring the most recent advancements in thrombocyte and granulocyte research set to take place from 27th to 29th September 2024. Among the diverse topics to be addressed, one of the sessions dedicated to "IgG Glycosylation as Sugar Switches" led by Gestur Vidarsson from the Department of Experimental Immunohematology at Sanquin Research, Amsterdam, and the Department of Biomolecular Mass Spectrometry and Proteomics at the Utrecht Institute for Pharmaceutical Sciences and Bijvoet Center for Biomolecular Research, Utrecht University, stands out. This session will delve into the complex world of IgG glycosylation and its profound impact on antibody function and immune regulation. Attendees will explore how subtle changes in sugar structures attached to IgG can act as switches, modulating the immune system's response to pathogens, vaccines, and autoimmunity. This cutting-edge research opens new avenues for therapeutic interventions, highlighting the importance of glycobiology in immunology. For full details on the symposium, including how to register and the entire program lineup, please visit our website at https://lnkd.in/e9Xvvuis.

  • This year, we are proud to host the 17th European Symposium on Platelet and Granulocyte Immunobiology (ESPGi), a premier event for exploring the most recent advancements in thrombocyte and granulocyte research set to take place from 27th to 29th September 2024. Among the diverse topics to be addressed, one of the sessions dedicated to "IgG Fc Receptors in Platelet Auto- and Alloimmunity" led by Alan H. Lazarus from the Department of Laboratory Medicine and Pathobiology at the University of Toronto, Canada, stands out. This session will delve into the critical role of IgG Fc receptors in destruction of antibody-coated cells and the immune modulation by antibodies. Data obtained in mouse models are currently also tested in in vitro models with human cells and offer a promise to understand antibody-mediated immunomodulation. For full details on the symposium, including how to register and the entire program lineup, please visit our website at https://lnkd.in/e9Xvvuis.

  • 💡 𝗟𝗮𝘀𝘁 𝗰𝗵𝗮𝗻𝗰𝗲 𝘁𝗼 𝘀𝗶𝗴𝗻 𝘂𝗽 𝘄𝗶𝘁𝗵 𝗽𝗿𝗶𝗰𝗲 𝗮𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲 Planning to join the 𝟭𝟳𝘁𝗵 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗼𝗻 𝗣𝗹𝗮𝘁𝗲𝗹𝗲𝘁 𝗮𝗻𝗱 𝗚𝗿𝗮𝗻𝘂𝗹𝗼𝗰𝘆𝘁𝗲 𝗜𝗺𝗺𝘂𝗻𝗼𝗯𝗶𝗼𝗹𝗼𝗴𝘆 (𝗘𝗦𝗣𝗚𝗜)? Register now and take advantage of the current lower price before it increases on September 1st. This is your chance to save while securing your place in a program that offers in-depth knowledge and insights into Platelet and Granulocyte Immunobiology. Learn more and sign up here: https://lnkd.in/e9Xvvuis

    • Geen alternatieve tekst opgegeven voor deze afbeelding
  • This year, we are proud to host the 17th European Symposium on Platelet and Granulocyte Immunobiology (ESPGi), a premier event for exploring the most recent advancements in thrombocyte and granulocyte research set to take place from 27th to 29th September 2024. Among the diverse topics to be addressed, one of the sessions dedicated to "Inherited Platelet Disorders: Which Omics?" led by Maartje van den Biggelaar from the Laboratory of Proteomics at Sanquin, Amsterdam, stands out. This session will show the use of proteomics with to explore bleeding disorders in more detail. The world of plasma proteins and platelet protein profiling is intriguing! This technology can be utilized to unravel the molecular underpinnings of bleeding disorders, aimed to lead to improved diagnostic methods and the development of targeted therapies. Make sure to register before September 1st to take advantage of the lower pricing. For full details on the symposium, including how to register and the entire program lineup, please visit our website at https://lnkd.in/e9Xvvuis.

  • This year, we are proud to host the 17th European Symposium on Platelet and Granulocyte Immunobiology (ESPGi), a premier event for exploring the most recent advancements in thrombocyte and granulocyte research set to take place from 27th to 29th September 2024. Among the diverse topics to be addressed, one of the sessions dedicated to "Tools to Study Megakaryocyte Biology" led by Julia Tilburg from the Department of Molecular Hematology at Sanquin Health Services in Amsterdam, stands out. This session will focus on the innovative tools and methodologies that have revolutionized our understanding of megakaryocyte biology. Attendees will learn about the cutting-edge techniques used to investigate megakaryocyte development, function, and their role in platelet production. This comprehensive overview will equip researchers with the knowledge and tools necessary to push the boundaries of megakaryocyte research further, opening up new possibilities for the treatment of hematological diseases. For full details on the symposium, including how to register and the entire program lineup, please visit our website at https://lnkd.in/e9Xvvuis.

  • This year, we are proud to host the 17th European Symposium on Platelet and Granulocyte Immunobiology (ESPGi), a premier event for exploring the most recent advancements in thrombocyte and granulocyte research set to take place from 27th to 29th September 2024. Among the diverse topics to be addressed, one of the sessions dedicated to "Drug-Induced Neutropenia" led by Brian Curtis from the Platelet and Neutrophil Immunology Laboratory at Versiti Blood Center of Wisconsin in Milwaukee, stands out. This session will delve into the complexities of drug-induced neutropenia, a significant and often challenging condition encountered in clinical practice. Attendees will gain a deeper understanding of the mechanisms behind drug-induced neutropenia, the latest diagnostic approaches, and strategies for management and treatment. This exploration promises to provide valuable insights into mitigating the risks associated with drug therapies and enhancing patient safety. For full details on the symposium, including how to register and the entire program lineup, please visit our website at https://lnkd.in/e9Xvvuis.

Gerelateerde pagina’s

Vergelijkbare pagina’s